Page 6 - Safina Jawaid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safina jawaid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safina Jawaid Today - Breaking & Trending Today

Bayer's blood thinner fails phase 3, denting $5B sales forecast

Bayer's blood thinner fails phase 3, denting $5B sales forecast
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Blackstone Life Sciences , Bristol Myers Squibb , Anthos Therapeutics , Blackstone Life ,

Asundexian Phase 3 AF Study Halted for Lack of Efficacy

The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF. ....

United States , North Carolina , Noacs Doacs , Christian Rommel , Manesh Patel , Global Head Of Research , Duke Clinical Research Institute , Medscape Cardiology , Global Head , Christian Ruff , Atrial Fibrillation , F Atrial Fibrillation , Anticoagulation Therapy , Erebrovascular Accident , Va Cerebrovascular Accident , Anti Thrombotics , Antithrombotic Therapy , Antithrombotic Agents , Ischemic Stroke , Monoclonal Antibody , Transient Ischemic Attack , Biologic Therapy ,

Bayers Halts Asundexian AFib Trial, OCEANIC-AF, for Inferior Efficacy

Bayer has announced the IDMC for OCEANIC-AF trial has recommended the trial be discontinued as a result of inferior efficacy. ....

Christian Rommel , Data Monitoring Committee , Global Head Of Research , Committee Of Bayer Ag Pharmaceutical Division , Independent Data Monitoring Committee , Executive Committee , Global Head ,

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anti

New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to increased risk of bleedingOCEANIC-AFINA, the latest Phase III study in the OCEANIC clinical trial program, will invest. ....

United States , Roxana Mehran , Christian Rommel , Xia Fxia , Bayer Ag , Haass International , Journal Of The American Heart Association , Interventional Cardiovascular Research , Global Head Of Research , International Society On Thrombosis , Drug Administration , Executive Committee , Global Head , Clinical Trials , Icahn School , International Society , Fast Track Designation , Reduced Dose Non , Vita Mink Antagonist Anticoagulants , Results From , Outcomes Registry , Better Informed Treatment , Atrial Fibrillation , American Heart , Oral Anticoagulants , Privately Insured Patients ,